PDF(Pubmed)
Abstract：
A maternal vaccine to protect newborns against invasive Streptococcus agalactiae infection is a developing medical need. The vaccine should be offered during the third trimester of pregnancy and induce strong immune responses and placental transfer of protective antibodies. Polysaccharide vaccines against S. agalactiae conjugated to protein carriers are in advanced stages of development. Additionally, protein-based vaccines are also in development, showing great promise as they can provide protection regardless of serotype. Furthermore, safety concerns regarding a new vaccine are the main barriers identified. Here, we present vaccines in development and identified safety, cost, and efficacy concerns, especially in high-need, low-income countries.
摘要：
保护新生儿免受侵袭性无乳链球菌感染的母体疫苗是不断发展的医学需求。该疫苗应在妊娠晚期提供，并诱导强烈的免疫反应和保护性抗体的胎盘转移。针对与蛋白质载体缀合的无乳链球菌的多糖疫苗处于开发的晚期阶段。此外,基于蛋白质的疫苗也在开发中，显示出巨大的希望，因为它们可以提供保护，无论血清型。此外，关于新疫苗的安全问题是确定的主要障碍。这里,我们介绍了正在开发的疫苗，并确定了安全性，成本,和功效问题，特别是在高需求的情况下，低收入国家。
